Tumor cells with mutation in BRCA1 or BRCA2 genes exhibit defective HR (referred to as BRCAness phenotype) and are pronounceably hypersensitive to ATM and PARP inhibition (83–85). This evidence concerns the gene BRCA1 and neoplasm.